🧾 What This Document Is

This is a preliminary proxy statement (PRE14A) for Skye Bioscience. Think of it as an invitation and information packet for the company's annual shareholder meeting. Its main job is to ask shareholders to vote on key proposals, like electing directors and approving company actions. It also includes a detailed "CEO letter" that explains the company's recent progress and strategy.

🏢 What The Company Does

👉 In simple terms, Skye Bioscience is a biotechnology company developing new medicines for obesity and metabolic diseases. Their lead approach is a "peripheral CB1 inhibitor" called nimacimab. The idea is to create a therapy that can be combined with today's popular weight-loss drugs (like semaglutide/Ozempic) to make weight loss better, more lasting, and with fewer side effects.

💊 The Clinical Story: A Key Year

The CEO letter highlights 2025 as a pivotal year for their main drug, nimacimab.

The Big Test (CBeyond™ Study): In a mid-stage trial, the combination of nimacimab and semaglutide showed promising results. After 26 weeks, patients on the combo lost more weight than those on semaglutide alone. By 52 weeks, the combo group achieved a 22.3% mean weight loss, with no sign of the weight-loss plateauing.
A Critical Learning: The trial also showed that nimacimab alone (monotherapy) wasn't very effective. However, the company believes this is a dose and exposure problem, not a flaw in the drug's science. They think the dose was too low to properly target the disease mechanism.
Safety Signal: The combination did not increase the common stomach-related side effects seen with semaglutide alone, and no brain-related side effects were observed with nimacimab—a key concern for this class of drugs.

🗳️ What You're Voting On

Shareholders will vote on four main proposals at the virtual annual meeting. The Board recommends voting FOR all of them.

Elect Six Directors: Vote to keep the current board members in place for another year.
Ratify the Auditor: Approve the selection of CBIZ CPAs P.C. as the company's accounting firm for 2026.
Increase Authorized Shares: Approve a 3x increase in the number of allowed common shares, from 100 million to 300 million. This gives the company flexibility for future needs like raising capital or acquisitions.
Approve Executive Pay: Hold a non-binding "say-on-pay" vote on the compensation of top executives.

👥 Meet the Board Nominees

Six directors are up for re-election. Here’s a snapshot of who they are and why they’re on the board:

Paul Grayson (Chairman, 61): Biotech CEO experience. Provides strategic leadership.
Deborah Charych, Ph.D. (62): Scientist and co-founder who helped sell a company to BMS for $4.1 billion. Brings deep drug development R&D expertise.
Punit Dhillon (45): The company's CEO. Leads day-to-day operations.
Annalisa Jenkins, MBBS (60): Former CEO and top R&D executive at major pharma companies (Merck, BMS). Brings clinical development and commercial experience.
Karen Smith, M.D., Ph.D. (58): Former Chief Medical Officer with a track record of getting multiple FDA-approved drugs. Expert in global R&D.
Andrew J. Schwab (55): Venture capitalist from 5AM Ventures. Provides financial and investment perspective.

👉 Why it matters: The board is a mix of scientific founders, seasoned drug developers, and financial experts. This team is designed to guide a clinical-stage biotech through complex R&D and potential partnerships.

⚖️ Governance & Compensation

Board Structure: The roles of Chairman (Paul Grayson) and CEO (Punit Dhillon) are separated for strong oversight.
Director Pay: In 2025, non-employee directors received a mix of cash fees (base ~$50k, plus committee fees) and stock option awards. Total compensation ranged from ~$109,000 to ~$369,000.
Clawback Policy: The company has a policy to recover incentive compensation from executives if financial results are later restated.
Anti-Hedging: Employees and directors are prohibited from hedging or speculating on company stock.

🔮 What's Next

20206 is focused on execution. Key milestones ahead include:

Getting data from a higher-dose expansion of the CBeyond study to solve the exposure question.
Advancing a new formulation for easier subcutaneous injection.
Moving the Phase 2b trial design forward with FDA feedback.
Continuing work on their broader "bioconjugate" platform for future metabolic drugs.

⚖️ Big Picture

👍 Strengths: Clear, differentiated clinical strategy in a hot market (obesity). Promising combo data with a potentially clean safety profile. A highly experienced board and management team.
⚠️ Risks: High-risk, high-reward biotech investment. The core science still needs to be proven at higher doses. Future trials are expensive and uncertain. Increasing authorized shares signals potential future dilution for shareholders.

🧠 The Analogy

Skye Bioscience is like a specialized pit crew working on a race car (semaglutide) that's already winning. They're not building a new car; they're adding a unique part (nimacimab) that they believe will make the car faster over the entire race, stop it from sputtering (side effects), and help it maintain its lead even after the finish line (durability).

🧩 Final Takeaway

This proxy is about re-electing an experienced board to oversee a critical transition year. The company is moving from early clinical promise to the definitive testing of its lead drug, nimacimab, at a higher dose. Shareholders are being asked to approve the team and the financial flexibility needed for this next, crucial phase.

Skye Bioscience, Inc. — PREM14A Filing